Synopsis:
Panacea Biotec Limited has secured a major domestic contract worth Rs.127.20 crores to supply the bivalent oral polio vaccine to the Central Medical Services Society, under the Ministry of Health and Family Welfare, Government of India.
The shares of a small-cap company that develops, manufactures, and sells pharmaceuticals and vaccines drew attention after the company received an order from the Central Medical Services Society under the Ministry of Health and Family Welfare.
With the market capitalization of Rs.2,672.06 crores, the shares of Panacea Biotec Limited are trading at Rs.436.5, up by 1.16 percent from its previous day’s closing price of Rs.431.25 per equity share.
Order
Panacea Biotec Limited has secured a major domestic order worth Rs.127.20 crores to supply the bivalent oral polio vaccine to the Central Medical Services Society, under the Ministry of Health and Family Welfare, Government of India. The vaccines will be delivered in multiple shipments over 90 to 480 days from the LOA date.
Also Read: Why did Jindal Group stocks skyrocket by up to 20% today? Check out the reason here
About the Company
Panacea Biotec is a research-focused biotechnology company engaged in the development, manufacturing, marketing, and distribution of pharmaceuticals and vaccines. It offers a portfolio of innovative prescription products across key therapeutic areas, including pain management, diabetes, renal diseases, osteoporosis, tuberculosis, gastrointestinal care, and vaccines.
The company’s revenue went up from Rs.115.72 crore in Q1FY25 to Rs.166.70 crore in Q1FY26. Net loss went down from Rs.15.88 crore in Q1FY25 to Rs.3.96 crore in Q1FY26. Its return on equity is negative 4.92 percent, and return on capital employed is negative 4.57 percent.
Written by Jhanavi Sivakumar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
